For a biotech CMO buying digital PR services, the first decision is not which publication to pitch. It is which claim the evidence can support—and which interpretation would go too far.
Science digital PR connects research sources with relevant journalists and business audiences. Use this guide to scope the work, assign scientific review and judge agency proposals without confusing a press-release distribution report with independent editorial coverage.
What is science digital PR?
Science digital PR is earned-media outreach for research organizations, biotechnology businesses and other technical brands. The work combines source-based explanation, expert access and targeted pitching. Treat independent editorial coverage, paid placements and press-release distribution as different deliverables; specify which you are buying before comparing agency proposals.
Decide whether you need a media story or a better source
Start the buying conversation with the research asset, not a placement target. Put the manuscript, methods, limitations and proposed audience in front of the team. Then decide what work is appropriate now.
A new finding with a clear source, an available scientific spokesperson and an identifiable audience may justify a targeted pitch. If the story depends on a result that the team cannot yet explain or document, commission source development first: interviews, a technical summary and a usable explanation of the limits.
There are also legitimate reasons to choose another route. An owned article can explain a specialized method in depth. A press release can provide an organization-controlled announcement. A paid placement can offer purchased distribution. Do not describe those outputs as independent earned coverage, and do not buy them under an ambiguous promise of media exposure.
Sometimes the right decision is to wait. Before tying outreach to a conference or publication date, establish what can be shared, when it can be shared and who is available to answer follow-up questions. A calendar opportunity is not a substitute for an explainable finding.
The Scientific Claim-to-Citation Ladder
Percepture's Scientific Claim-to-Citation Ladder is a new editorial planning model connecting source documents, technical review, media outreach and commercial measurement. It applies an audience-and-sales perspective to scientific communications; it is not a substitute for scientific validation or regulatory review.
- Source: Interview the scientific team and collect the underlying documents.
- Separate: Distinguish findings, hypotheses, implications, limits and regulatory status.
- Translate: Write audience-specific explanations from the same evidence.
- Pitch: Approach relevant editors with sources and expert access.
- Measure: Track accurate coverage, useful citations and qualified conversations.
1. Interview the scientist before writing the headline
Ask the scientific subject-matter expert to explain what was investigated, how the work was conducted and what would be an incorrect interpretation. Request the source behind each proposed central claim—not just the presentation slide that summarizes it.
Create a short source card containing the document version, publication status, relevant methods, approved spokesperson and limitations that must travel with the story. Record permission to share supporting materials. Keep confidential research, personal information and commercially sensitive details out of the public press kit unless their release is authorized.
The most useful interview question is often: What would you correct if a journalist wrote this tomorrow? Use the answer to improve the pitch before it leaves the organization.
For the broader owned-content program, Percepture's life sciences content marketing guide is a related planning resource. Keep this PR workstream focused on what an outside editor needs to understand and investigate the story.
2. Separate what happened from what it might mean
Give each important sentence a job. A finding describes what the work reports. A hypothesis proposes an explanation to investigate. An implication describes possible significance. A limitation defines where the interpretation must stop.
Keep regulatory status in its own field. Record exactly what the organization is authorized to say about the specific product or use; do not substitute publication status, peer review or scientific enthusiasm for that determination.
Assign scientific accuracy to a named technical owner. Assign medical, legal and regulatory questions to the appropriate qualified reviewers—often grouped as MLR review. The communications lead should own the readable final version and the record of which version was cleared for release.
For U.S. messaging, include the FTC advertising and marketing guidance in the legal team's reference set. Ask reviewers which FDA or FTC requirements apply to the actual message, product, audience and distribution plan. Do not ask an agency copywriter to make that determination alone.
3. Translate once, then adapt the depth
Prepare one evidence-based account before writing different versions for journalists, scientists, executives and investors. Change the vocabulary and level of detail—not the underlying claim.
The journalist-facing version should answer three questions quickly: what is new, why this audience should care and where the supporting material can be examined. A technical attachment can carry the methods and detailed caveats. An executive summary can explain the business question without turning a possible application into an established capability.
Place important limits beside the relevant claim. Do not rely on a distant footnote to repair an overconfident headline.
For investor or business-development materials, separate the research finding from the proposed commercial application. Ask the scientific team what additional work would be necessary before making the next claim. That distinction gives commercial readers a more useful conversation than an unsupported promise.
4. Match the story to the editor, audience and timing
Build the media list around the reader's decision. For a research-tools business, that might mean scientists evaluating a method or laboratory leaders considering a workflow. For a biotech company, define whether the intended audience is potential partners, investors or a particular scientific community.
Ask an agency to explain why each priority outlet and reporter belongs on the list. Review recent relevant reporting, the intended audience and the proposed angle. Use a domain-quality metric as one input, not as the definition of editorial relevance or story quality.
A preprint is a manuscript shared before peer review. Before pitching one, check the target journal or conference's policies, existing public availability and any embargo. If outreach is appropriate, identify the work as a preprint in both the pitch and supporting materials.
For embargoed material, document the exact release time and time zone, what recipients may access and who owns last-minute changes. Give journalists access to the underlying source and an available expert. Ask the agency how it handles factual corrections without promising control over independent editorial decisions.
5. Measure accuracy before celebrating exposure
Define an acceptable piece of coverage before launch. Consider whether it identifies the source, preserves the central finding, includes material limits and reaches the intended audience. Record factual corrections separately from placement totals.
Then connect coverage to business activity. Track relevant referral visits, source requests, qualified partner discussions, RFPs and investor conversations where appropriate. Define a qualified conversation with the commercial team before counting one.
Percepture's marketing attribution and analytics work is the adjacent discipline for designing that reporting. Keep observed referrals, self-reported discovery and broader campaign influence separate. Do not assign all subsequent pipeline to an article simply because it appeared first.
For AI-search monitoring, maintain a separate record of the questions tested, the sources cited and whether the research was summarized accurately. Treat a captured citation as an observation, not a promised future placement. Ask an agency to explain its monitoring method rather than offering guaranteed AI visibility.
A worked example: a laboratory comparison, not a clinical launch
Input assumptions: This is a fictional research-tools company with a draft manuscript comparing two sample-preparation workflows under specified laboratory conditions. The manuscript has not undergone peer review. The work does not evaluate clinical use. No performance result, customer outcome or regulatory authorization is assumed.
Under those assumptions, the communications job is to explain the comparison and invite scrutiny—not to announce a clinical benefit.
What changes during claim review?
| Decision | Recommended treatment | Supporting input |
|---|---|---|
| Lead angle | Explain the laboratory comparison and the question it investigates. | The manuscript’s methods and stated research question. |
| Publication status | Describe the manuscript as not yet peer-reviewed. | The assumed draft status. |
| Clinical relevance | State that the work does not evaluate clinical use; omit clinical-benefit claims. | The assumed study scope. |
| Media preparation | Prepare the methods, limitations and a scientist’s explanation before selecting an outreach date. | The source documents and an accountable technical spokesperson. |
An illustrative pitch opening would be: “A research team has prepared a manuscript comparing two sample-preparation workflows under specified laboratory conditions. The manuscript has not undergone peer review, and the work does not evaluate clinical use.”
That opening still needs a meaningful research question and source material before it becomes a compelling pitch. Its value is precision: it establishes what the journalist is being invited to examine without inventing a result.
What to put in an agency scope
When comparing science digital PR proposals, ask each agency to scope the same source asset and audience. Otherwise, one proposal may price technical discovery while another assumes that all scientific review and source preparation are already complete.
Use the same questions for every proposal
| Workstream | Ask for | Clarify before signing |
|---|---|---|
| Scientific discovery | The interview plan, required documents and source-card deliverable. | Who supplies technical expertise, and how much internal time is required? |
| Review and revisions | A versioned approval workflow with named responsibilities. | Which revisions are included, and who resolves scientific or regulatory questions? |
| Media outreach | A reasoned outlet shortlist, proposed angles and follow-up responsibilities. | Are earned outreach, release distribution and paid placements priced separately? |
| Reporting | Coverage-quality criteria and a defined commercial handoff. | What is counted, what is merely observed and what cannot be attributed? |
Set the budget denominator before comparing fees. Include agency costs, internal scientific and review time, production and separately purchased distribution. Then distinguish cost per qualified piece of coverage from cost per documented qualified conversation. They answer different questions.
For the latter, divide total campaign cost by documented qualified conversations during the agreed observation period. If none are observed, report that outcome directly; do not present a zero cost per conversation. This is an efficiency calculation, not proof of incremental revenue.
An in-house team may be the better fit when it already has scientific access, writing capacity and relevant media relationships. An agency proposal should explain the specific capability or capacity it adds. Ask for relevant public work and identifiable coverage, but evaluate the source fidelity and audience fit—not simply the number of logos in a presentation.
Finally, decide who handles the next step after attention arrives. Connect the approved source page, commercial follow-up and other distribution through an omnichannel marketing plan. A useful inquiry should have an owner; a technical question should reach someone able to answer it accurately.
Compare scope before comparing fees
Use one research asset, one intended audience and the review responsibilities above as the basis for your pricing conversation. Separate scientific preparation, earned outreach, purchased distribution and reporting in the proposed scope.
About Bob Generale
Bob Generale is president of Percepture, an early digital marketing and public relations practitioner, and a pioneer of digital PR. His perspective connects public relations, search visibility and commercial decision-making rather than treating coverage as a standalone finish line. For scientific founders and biotechnology marketing leaders, this guide applies that perspective to source-led storytelling, technical review and measurement tied to relevant conversations. Percepture’s own editorial guide features Bob as one of the world’s best AI SEO experts; this is recognition from Percepture’s guide, not an independent award or global ranking. His emphasis here is practical: align communications and sales around the same audience, preserve the distinction between evidence and interpretation, and judge visibility alongside the decisions it helps buyers make.
